<p>Gnathic osteosarcomas (OS) are a rare subset of osteosarcomas, primarily localized to the mandible and maxilla. These tumors are characterized by their distinct clinical behavior, including locally aggressive behavior but a lower tendency for metastasis and differential response to adjuvant therapy, compared to other osteosarcomas of other body parts. The present study was conducted to describe the clinicopathological features of osteosarcomas of the jaws, with an emphasis on immunohistochemical characterization. A retrospective study was done in the electronic database and department archives to retrieve all the cases of osteosarcomas reported in the department from 2007 to 2024, totally 14 cases were identified and paraffin blocks were obtained. All 14 cases were resorted to immunohistochemistry against the markers Ki67, MDM2, and SATB2 using standard operating protocol. The results were documented in an Excel sheet. The mean age of the patients included in the study was 32&#xa0;years, and a slight female predilection was observed. Histopathologically, the osteoblastic variant was the most common subtype observed. The Ki-67 proliferation index ranged from 20 to 50%. MDM2 expression score of 3 was observed in 70% of the cases, and SATB2 expression was positive in all cases included. In the present study, no metastasis was noted; however, a single case showed recurrence within 6&#xa0;months of surgery. Osteosarcomas of the jaws are a group of rare subset of locally aggressive bone tumors, showing high proliferative index but demonstrate a lower metastatic potential. SATB2 is a sensitive marker, while MDM2 may have a limited role in high-grade osteosarcoma, in contrast to low-grade osteosarcoma. More studies with a higher sample size are warranted to assess if these markers are correlated with targeted therapies.</p>